Tumor-on-Chip as a Personalised Platform for Rapid Drug-Testing in Breast Cancer
Clara Helal(Institut Curie), Stéphanie Descroix(Centre National de la Recherche Scientifique), Élodie Montaudon(Institut Curie), Maxime Simon(Centre National de la Recherche Scientifique), Léa Pinon(Centre National de la Recherche Scientifique), Gianni Antonelli(Centre National de la Recherche Scientifique), Anne Vincent‐Salomon(Université Paris Sciences et Lettres), Laura Sourd(Institut Curie), Elisabetta Marangoni(Institut Curie), Gérard Zalcman(Inserm), Maria Carla Parrini(Inserm), Luc Cabel(Université de Versailles Saint-Quentin-en-Yvelines), Héloïse Derrien(Institut Curie), Angela Bellini(Institut Curie), Andreia Goncalves(Institut Curie), Toulsie Ramtohul(Université Paris Sciences et Lettres), Niccolo Schintu(Centre National de la Recherche Scientifique), Martin Nurmik(University of Luxembourg)
Cited by 0
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
|Cancer Cell|2018|1.7k
In search of definitions: Cancer‐associated fibroblasts and their markers
|International Journal of Cancer|2019|733
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
|Nature Medicine|2022|637
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
|Nature Genetics|2015|563